Cardiovascular disease (CVD) is the most common cause of death and disability worldwide [1-5]. Stable angina represents a chronic, often life-long condition involving approximately 2% and 4% of the general population in Europe and United States [1,2,6], and which may and significantly impact quality of life and adversely compromise the activities of daily living [3,4]. In addition, the majority of patients with stable angina have several comorbidities including; hypertension (HTN), diabetes mellitus (DM), dyslipidemia, atrial fibrillation (AF) and heart failure (HF) [1,5].
